Charles J. Dimitroff
Charles J. Dimitroff writes for The Conversation on how cancer reshapes its surroundings and how immune cells can be engineered to fight back inside that hostile terrain. His coverage centres on the tumor microenvironment and the sugar biology of immune cells, showing how these hidden layers of cancer immunology determine whether treatments like CAR-T cell therapy succeed or fail. He draws on his work in cellular and molecular medicine at Florida International University, where he studies how carbohydrate-binding proteins and engineered “sugar shields” alter immune cell behaviour in cancer.
Tumors’ hostile microenvironment
Dimitroff’s flagship piece for The Conversation, “Killing cancer requires immune cells to infiltrate tumors’ hostile microenvironment – sugar shields can help them break in,” sets the frame for his coverage. In it, he explains that cancers build an ecosystem of cells and structural components that controls what can enter, what actions immune cells can take once inside, and how long those cells survive. He describes this tumor microenvironment as a set of defenses that lets cancer withstand the body’s natural immune attacks and ride out shifts in temperature and oxygen levels that would normally be harmful. The focus is not on individual drugs but on the physical and biochemical barriers that surround tumors, from dense tissue to molecular signals that repel or disable immune cells.
Across this work, Dimitroff’s distinguishing angle is to treat the microenvironment as the main story rather than a background detail. He walks readers through how immune cells must adhere to blood vessels, migrate through tissue and remain functional in a disruptive chemical landscape before they ever reach a cancer cell. He uses clear metaphors around ecosystems and hostile territory while still naming the underlying mechanisms, such as how specific sugars and receptors on cell surfaces govern these steps. This gives his health coverage a systems view of cancer that links microscopic interactions to clinical outcomes, without drifting into general lifestyle or oncology news.
Sugar shields and glycoengineered CAR-T cells
A second, recurring thread in Dimitroff’s work is the idea that immune cells can be re-designed at the level of their sugar coatings to survive in and penetrate tumors. In the same Conversation article, he introduces “sugar shields” as protective layers on engineered immune cells that help them endure the harsh conditions within tumors and keep functioning long enough to kill cancer cells. Outside of that platform, public descriptions of his lab’s work highlight glycoengineered CAR-T cells that are given a “sugar-coated shield” to help them survive the tumor microenvironment and maintain their anti-cancer activity. These accounts emphasise that his group is not only studying cancer biology but actively redesigning immune cells using glycobiology tools so they can overcome the barriers he describes.
This focus on sugar shields distinguishes his coverage from generic reporting on immunotherapy, which often centres on new targets or drug approvals. Dimitroff writes about how altering the carbohydrate structures on CAR-T cells changes their interactions with tumor stroma, blood vessels and suppressive immune cells, giving readers a mechanism for why some engineered cells falter once they reach solid tumors. He positions glycoengineering as a bridge between basic molecular biology and front-line therapies, using accessible language but keeping the details of how specific sugar modifications can be tuned as part of treatment design. For story fit, this makes him a specialist voice on the interface between CAR-T technology and the physical realities of solid cancers, rather than on cancer care broadly.
Galectins and immune surveillance
Dimitroff’s explainer work is underpinned by a long research record on galectins, the family of sugar-binding proteins that shape how immune cells move, adhere and respond. In a conceptual piece on cancer immunotherapy, co-authored in a biomedical journal, he explores how galectin inhibitors can enhance tumor immune surveillance, framing these molecules as levers that can keep immunotherapies engaged against cancer. Earlier experimental work shows galectin-9 bridging human B cells to vascular endothelial cells and slowing their movement across the vessel wall, demonstrating how specific sugar-binding interactions control immune cell trafficking. He has also studied monomeric forms of galectin-1 and how galectin-1 ligand binding influences the fate and function of effector T cells, linking carbohydrate recognition directly to T cell survival and activity.
These themes carry through into his health writing by keeping attention on immune cell adhesion, migration and persistence, rather than only on their ability to recognise cancer. When he explains why tumors are hard to treat, he brings in the idea that sugar-binding proteins and their ligands can act as molecular brakes or guides on immune cells, echoing the mechanisms he has dissected in the lab. His pieces therefore sit at the intersection of molecular biology and health reporting: they translate complex glycobiology and immunology into clear narratives about why current cancer therapies struggle, and how targeted changes to sugar interactions could make them more durable. This makes his coverage particularly relevant to stories about next-generation immunotherapies, tumor microenvironment-modifying strategies, and research-driven approaches to improving immune surveillance in cancer.
4 more health journalists.
Abida Tasnim
Abida Tasnim is a health writer for The Daily Star who focuses on clear, practical guidance that helps readers recognise risks early and act before everyday illnesses turn into wider public health problems. She reports on infectious disease prevention, using measles coverage to show how outbreaks start with individual decisions and behaviours, not just hospital statistics. Her work explains what happens during an outbreak and then anchors the story in simple steps people can take, such as avoiding crowded places when symptoms appear, practising good hygiene, and seeking medical advice early. She writes direct, action‑oriented health explainers that turn clinical questions about contagion and disease burden into everyday choices. Across her beat, she stresses early recognition, timely care, and prevention as the foundations of healthier communities.
Adrián Carballo Casla
Adrián Carballo Casla stands out for turning complex cohort data on ageing into clear, food‑level advice on what older adults should eat to protect brain health and slow chronic disease. He is a researcher in nutritional epidemiology focused on ageing and chronic disease prevention and a postdoctoral researcher in geriatric epidemiology at Karolinska Institutet, writing health explainers for The Conversation. He reports on how diet quality, especially Mediterranean and Mind‑style patterns, shapes dementia risk, grey matter loss and neurocognitive ageing, and how healthy versus pro‑inflammatory diets alter multimorbidity trajectories. His articles translate findings on flavonoids, polyphenols, folate, omega‑3 fats and dietary nitrates into specific food choices and small, practical changes. Much of his coverage is anchored in his own studies on multimorbidity, high‑risk older adults and tailored dietary recommendations, often syndicated to other outlets.
Ahmed Elbediwy
Ahmed Elbediwy brings a lab-based understanding of cancer biology and clinical biochemistry to public-facing health reporting, linking drug mechanisms and molecular pathways to everyday choices about medicines and products. He writes for The Conversation on weight-loss injections, cancer overdiagnosis and anti-ageing supplements, focusing on obesity medicine, cancer signalling, screening trade-offs, skincare and supplement science. His pieces on GLP-1 drugs such as Ozempic, Wegovy and Mounjaro explain why some people do not respond, how gut hormones and appetite signals work, and where psychological support and nutrition fit alongside prescriptions. He co-authors explainers on cancer risk and overdiagnosis and on whether supplements can reverse ageing, separating established knowledge from emerging research. An award-winning senior lecturer at Kingston University, he favours clear, structured explainers, careful definition of key terms and evidence-based appraisal over hype.
Amanda Sheppeard
Amanda Sheppeard is a managing editor and health journalist known for long, detailed explainers that connect complex clinical research, disability policy and political narratives with the daily realities of doctors and patients. She works at The Medical Republic across editorial leadership and commercial content while reporting widely on medicine for its specialist titles. Her real beat spans autism, disability policy, autoimmune disease, infectious threats and system pressures in primary care and hospitals. She covers subjects such as autism diagnosis and the NDIS, rheumatology’s clinical shifts, weight-loss agents in rheumatoid arthritis, infection control, antimicrobial resistance and new modalities like CAR T-cell therapy and microneedles. She reports by doing the synthesis inside the story, linking trial design, molecular targets, funding rules and policy changes to concrete decisions and workflows in clinics and hospitals.